TY  - CHAP
M1  - Book, Section
TI  - Aminoglycosides
A1  - MacDougall, Conan
A1  - Chambers, Henry F.
A2  - Brunton, Laurence L.
A2  - Chabner, Bruce A.
A2  - Knollmann, Björn C.
PY  - 2015
T2  - Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e
AB  - The  aminoglycoside  group  includes  gentamicin,  tobramycin,  amikacin,  netilmicin  (not  available  in  the  U.S.),  kanamycin,  streptomycin,  paromomycin,  and  neomycin.  These  drugs  are  used  primarily  to  treat  infections  caused  by  aerobic  gram-negative  bacteria;  streptomycin  is  an  important  agent  for  the  treatment  of  tuberculosis,  and  paromomycin  is  used  orally  for  intestinal  amebiasis  and  in  the  management  of  hepatic  coma.  In  contrast  to  most  inhibitors  of  microbial  protein  synthesis,  which  are  bacteriostatic,  the  aminoglycosides  are  bactericidal  inhibitors  of  protein  synthesis.  Mutations  affecting  proteins  in  the  bacterial  ribosome,  the  target  for  these  drugs,  can  confer  marked  resistance  to  their  action.  However,  most  commonly  resistance  is  due  to  acquisition  of  plasmids  or  transposon-encoding  genes  for  aminoglycoside-metabolizing  enzymes  or  from  impaired  transport  of  drug  into  the  cell.  Thus,  there  can  be  cross-resistance  between  members  of  the  class.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2023/09/29
UR  - accessbiomedicalscience.mhmedical.com/content.aspx?aid=1127870722
ER  -